medellin
(5)
Amir Reiter Bet the Agency on a Marketplace - Then Went Back to the Work That Mattered
CloudTask’s founder traded a profitable service business for a risky marketplace, learned where software ends and trust begins, and rebuilt around a stubborn idea: careers compound when companies invest in people before they look obvious.
The Medellin Agency That Learned to Sell to America in Two Languages
It began in 2003 with one text message. Two decades later, SM Digital runs paid search, social, and lead-gen for brands across two continents - and built its whole model on the idea that the fastest-growing market in the U.S. speaks Spanish.
Palomma
Palomma is a Medellin-based fintech building an AI-native banking platform for real estate in Latin America, starting with rent. It deploys AI agents that handle leasing, sales, and collections for property managers across WhatsApp, SMS, and phone calls 24/7, then layers on payment collection and disbursement to own the flow of rent and monetize it through credit and insurance products. Founded in the Y Combinator Winter 2023 batch, the company originally launched as a frictionless Pay-by-Bank API for LatAm merchants before pivoting to real estate.
Telepatia AI
Telepatia AI is a healthtech company building an 'AI Doctor' for Latin America - a clinical copilot that transcribes patient visits in real time, structures the medical record automatically, and surfaces evidence-based suggestions while the physician works. Founded by Colombians Nicolas Abad and Tomas Giraldo and incubated at Stanford, the platform integrates with 50+ hospital systems, claims to give physicians back roughly two hours a day, and has raised $42M total, including a $33M Series A led by Andreessen Horowitz. Its stated goal is to assist half of Latin America's 1.9 million doctors by the end of 2027.
Nicolas Abad
Nicolas Abad is the co-founder and CEO of Telepatia, a Latin American healthtech company building AI healthcare workers - starting with an 'AI Doctor' that transcribes consultations, reviews records, flags drug interactions, and surfaces clinical guidance in real time. Named after his late father's nickname, the company grew from a Stanford MBA side obsession to a venture backed by Andreessen Horowitz, reaching more than 14 million patients across five countries inside its first year. Abad's stated ambition is audacious to the point of comedy: win Latin America's first Nobel Prize in Medicine since 1984 by turning healthcare from scarcity into abundance.